Table 1.
Demographic and clinical features of patients with macrophage activation syndrome
| Tocilizumab | Historic cohort | |||||
|---|---|---|---|---|---|---|
| Full-blown | Possible | All | Full-blown | Possible | All | |
| Number | 2 | 10 | 12 | 10 | 8 | 18 |
| Sex, no. | ||||||
| Female | 1 | 7 | 8 | 3 | 5 | 8 |
| Male | 1 | 3 | 4 | 7 | 3 | 10 |
| Age, median (IQR) | 6 (3–9) | 8.5 (7–14.75) | 8.5 (7–12.75) | 5 (1.75–6.75) | 8 (3.5–9.5) | 5.5 (2–8.25) |
| Fever (%, n) | 50 (1/2) | 50 (5/10)* | 50 (6/12)** | 90 (9/10) | 100 (8/8)* | 94.4 (17/18)** |
| Hepatosplenomegaly (%, n) | 0 (0/2) | 30 (3/10) | 25 (3/12) | 40 (4/10) | 37.5 (3/8) | 38.9 (7/18) |
| Lymphadenopathy (%, n) | 0 (0/2) | 20 (2/10) | 16.7 (2/12) | 30 (3/10) | 37.5 (3/8) | 33.3 (6/18) |
| CNS (%, n) | 0 (0/2) | 0 (0/10) | 0 (0/12) | 0 (0/10) | 0 (0/8) | 0 (0/18) |
CNS Central nervous system, * = p < 0.05; ** = p < 0.01;